The aim of this study was to determine the relative safety of 4 antiviral drugs (telbivudine, tenofovir, adefovir, and entecavir) against hepatitis B virus with respect to kidney function and toxicity in male Sprague Dawley rats. The antiviral drugs were administered once daily for 4 weeks by oral gavage at $10 and 25-40 times the human equivalent dose. Main assessments included markers of renal toxicity in urine, magnetic resonance imaging (MRI) of kidney function, histopathology, and electron microscopic examination. Administration of adefovir at 11 and 28 mg/kg for 4 weeks caused functional and morphological kidney alterations in a time-and dose-dependent manner, affecting mainly the proximal tubules and suggesting a mechanism of toxicity related to mitochondrial degeneration/depletion. Of note, the observed adefovir-induced reduction of kidney function was not detected by the standard method of glomerular filtration rate (GFR) measurements (clearance rate of the endogenous marker, creatinine), thereby emphasizing the superiority of MRI in terms of sensitive detection of GFR in rats. For the low dose of 300 mg/kg of tenofovir, minor kidney effects such as nuclear enlargement in the tubular epithelium, and hyaline droplets accumulation were detected, which was also observed for the low dose (11 mg/kg) of adefovir. No assessments could be done at the higher dose of 600/1000 mg/kg tenofovir due to gastrointestinal tract toxicity which prevented treatment of the animals for longer than 1 week. Entecavir at 1 and 3 mg/kg and telbivudine at 600 and 1600 mg/kg caused no toxicologically relevant effects on the kidney.
Telbivudine, tenofovir, entecavir, and adefovir are nucleos(t)ide analogues currently used in oral treatment of hepatitis B and HIV therapy. These antiviral drugs are all primarily excreted unchanged through renal route (Fontana, 2009) . Several antiretroviral drugs have been reported to cause renal toxicity in patients and the 2012 guidelines of the European Association for the Study of Liver (EASL) stated that renal function decline has been reported with all hepatitis B antiviral drugs except perhaps for telbivudine, which seems to improve the creatinine clearance (EASL, 2012) . Indeed, recent studies suggested that telbivudine has a renal-sparing effect (Chan et al., 2012; Gane et al., 2013) , in contrast to most other oral nucleos(t)ides against hepatitis B virus (James et al., 2004; Liaw et al., 2011a,b; Tamori et al., 2010) . The nephrotoxic potential seems to be higher for the 2 nucleotide analogues (adefovir and tenofovir), which are associated with significant direct nephrotoxicity as reported in their respective Summary of Product Characteristics, particularly adefovir (Ha et al., 2009) . The EASL guidelines recommend appropriate on-treatment monitoring of glomerular filtration rate (GFR) in all patients receiving nucleotide analogue therapy (adefovir or tenofovir) and monitoring of GFR in high-risk patients receiving nucleoside analogue therapy (lamivudine, telbivudine, or entecavir) (EASL (2012) .
In patients with tenofovir nephrotoxicity, glomeruli in kidney biopsies were normal, but tubular epithelial cells were apoptotic or necrotic (Herlitz et al., 2010; Izzedine et al., 2005) . The target of tenofovir toxicity appeared to be the proximal tubule and the early signs of renal toxicity were a Fanconi syndrome (with hypophosphatemia, glucosuria, and aminoaciduria).
The purpose of this exploratory study in rats was to compare the effects of telbivudine, tenofovir, entecavir, and adefovir on the kidney after repeated oral administration at $10 and 25-40 times human equivalent dose (HED) (as calculated by the body surface area) for 4 weeks. Earlier time points (Days 3 and 10) were also included in this study to identify initial events in the manifestation of renal toxicity. Readouts of histopathology, immunohistochemistry, and electron microscopy of the kidney, clinical chemistry in plasma and urine with additional sensitive urinary markers for early detection of kidney alterations, as well as magnetic resonance imaging (MRI) to investigate the time course of functional effects on the renal GFR were performed. Furthermore, potential effects on the liver and skeletal muscle were assessed by clinical chemistry and post-mortem investigations.
MATERIALS AND METHODS

Animals
A total of 216 male Hsd:Sprague Dawley rats (Harlan Laboratories B.V., Venray, The Netherlands) with an age of 9-10 weeks and body weight of 265-346 g (at start of dosing) were used in this study. The rats received pelleted standard diet (Provimi Kliba AG, Kaiseraugst, Switzerland), which was provided ad libitum. Tap water was available ad libitum from polyethylene bottles.
This study was performed in conformity with the Swiss Animal Welfare Law and specifically under an Animal License approved by the Cantonal Veterinary Office of Basel.
Administration of study drugs and justification for dosing
Telbivudine (Batch C0048; Novartis Pharma AG, Switzerland), entecavir (batch 1-BKG-17-1; Toronto Research Chemicals Inc., Toronto, Canada) and adefovir (adefovir dipivoxil, batch BCBC0377V; Sigma-Aldrich, Buchs, Switzerland) were suspended or dissolved in aqueous 0.5% carboxymethyl cellulose (CMC sodium salt, medium viscosity). Tenofovir (Viread V R tablets, batch 10VR028D; Gilead Sciences, Zug, Switzerland) was dissolved in purified water. Study drugs were administered orally by gavage once daily in the morning, with dosages adjusted to actual daily body weight, to groups of eight male Sprague Dawley rats each, at 2 different dosages for 3, 10, and 28 days using a dosage volume of 10 ml/kg. Groups were started staggered by duration of doses. The dosages (as base) were 600 and 1600 mg/kg for telbivudine, 300 and 1000 mg/kg for tenofovir (367 and 1224 mg/kg as fumarate salt), 1 and 3 mg/kg for entecavir, and 11 and 28 mg/kg for adefovir. The first 4 animals treated with tenofovir at 1000 mg/kg were sacrificed early on Day 6 due to severe clinical signs and progressive body weight loss. The remaining animals of this group with later treatment start received tenofovir at 600 mg/kg (734 mg/kg as fumarate) from Day 1 until early termination on Day 7 in similar condition.
Concurrent control animals were similarly treated with the vehicle (aqueous 0.5% CMC solution) at 10 ml/kg. Dose levels were chosen to achieve similar multiples of the recommended therapeutic human equivalent dose (HED) based on body surface area (BSA), with a low dose of $10 times HED, and a high dose of $25 times HED for telbivudine and adefovir, $30 times HED of entecavir, and $40 times HED for tenofovir.
Schedule of assessments
The following in-life examinations were performed: mortality, clinical signs (daily), body weight (once during pretest, daily during the treatment period) and water consumption (Days 7-9 and Days 25-27 during 4-week treatment period). All routine clinical biochemistry parameters in blood and urine, as well as additional specific urinary markers of renal toxicity from Myriad RBM rat kidney map panel, were assessed at pre-test, and on Days 2, 9, and 27. MRI was performed to assess kidney function on Days 3, 10, and 28. Exposure of test drugs was measured in plasma and in kidney tissue on Days 3, 10, and 28, and in liver and skeletal muscle tissue on Day 28. Post-mortem investigations consisted of macroscopic examination, organs weight (brain, kidneys, liver) and histopathology of kidney (assessed on Days 3, 10, and 28), liver and skeletal muscle (assessed on Day 28). Additional immunohistochemistry and electron microscopic examinations were performed on kidney specimens collected from selected animals on Day 28.
Clinical pathology investigation
Standard clinical biochemistry parameters (including serum urea and creatinine concentrations) were assessed from blood samples taken from the tongue vein under anesthesia with isoflurane.
Urine was collected over a period of $6 h into tubes cooled with ice water. Volume, standard urinalysis (reagent strip reactions), urine clinical biochemistry (including creatinine and total protein concentrations), cystatin C (measured by ELISA), and a panel of kidney injury biomarkers comprising beta-2-microglobulin, calbindin, clusterin, epidermal growth factor, glutathione S-transferase-alpha (GST-a), glutathione S-transferase-Yb1 (GST-Yb1), kidney injury molecule-1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL), osteopontin, tissue inhibitor of metalloproteinase-1 (TIMP-1), and vascular endothelial growth factor (VEGF) were determined. The panel of kidney injury biomarkers was measured at Rules-Based Medicine (RBM) Inc., Austin, Texas. Concentration/activity of all the analytes measured in the urine was normalized to the urine creatinine concentration in order to reduce the variability caused by the amount of water excreted by kidneys.
Glomerular filtration rate was determined from the creatinine and cystatin c clearance rates over a 6-h time period calculated from urine and serum concentrations of creatinine and cystatin c measured by Jaffe's reaction (Roche) and ELISA (Rat Cystatin C ELISA Kit, Cat. No.: RD391009200R, BioVendor Research and Diagnostic Products, Brno, Czech Republic), respectively, and urine volume. [Example of calculation: GFR¼ (Creatinine concentration in urine/creatinine concentration in plasma) x (6 h Volume/360)]. Additionally, GFR was also assessed by MRI as described below.
Toxicokinetics
In Week 3, blood was taken (4 animals per time point) at the following time points: 1-, 3-, 7-, and 24-h post-administration.
Additionally blood was taken at necropsy on Days 3, 10, and 28. The toxicokinetics parameters (C max , C max /dose, AUC 0-24 h , AUC 0-24 h /dose, T max ) were assessed for telbivudine, tenofovir, entecavir, or adevovir using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). Concentrations of the study drugs were also determined in kidney on Days 3, 10, and 28, liver and skeletal muscle (gastrocnemius) on Day 28. The bioanalytical determinations of the test drugs in plasma and tissues were performed at Quality Performance Service (QPS), Newark, Delaware.
Magnetic resonance imaging of the kidneys
Magnetic resonance imaging on isoflurane-anesthetized, spontaneously breathing rats was used for the noninvasive analysis of functional changes in the kidney. Experiments were performed on a 4.7-T Bruker Biospec MRI system (Bruker Biospin, Ettlingen, Germany) equipped with a self-shielded 12-cm bore gradient system capable of switching 200 mT/m in 170 ls. A proton birdcage resonator with diameters of 72 mm (Bruker Biospin) was used for radiofrequency excitation and detection. After placing a rat in the magnet, scout fast images were acquired for localization purposes. The acquisition of functional data was performed using a gradient-echo sequence with the following parameters: repetition time 10.6 ms, echo time 2.24 ms, field-of-view 70 mm Â 60 mm, matrix 128 Â 48, slice thickness 1.5 mm, number of repetitions 6, flip angle of the radiofrequency excitation 25
. The acquisition time for one image was of 3.05 s. In one session, 170 images of the same slice were acquired sequentially. Following the acquisition of 15 baseline images, a paramagnetic contrast agent (gadolinium-tetraazacyclododecanetetraacetic acid; Gd-DOTA, Dotarem V R , Guerbet, Roissy, France; 20 ml/100 g body weight) was administered intravenously as a bolus and then flushed with 0.3 ml of saline within 2 s. Following the bolus injection of the contrast agent, the mean signal intensities within the regions-of-interest (cortex or outer medulla) for each of the 170 images were calculated as previously described in detail (Baumann and Rudin, 2000; Egger et al., 2015; Laurent et al., 2002; Sari-Sarraf et al., 2008) . For assessing functional changes, the parameters time to peak (TTP), and area under the curve (AUC) of the first 100 s following Gd-DOTA injection, were calculated.
Post-mortem sample preparation
At termination of each arm of the study, animals were euthanized by exposure to carbon dioxide followed by exsanguination. Kidneys were weighed, and the right kidney was further divided by 3 transversal sections with the middle piece fixed in buffered formalin, and the poles embedded in OCT (Optimum Cutting Temperature) compound and immediately frozen in isopentane (2-methylbutane) pre-chilled on liquid nitrogen for gene expression analysis and molecular morphology. The left kidney was transversally halved with one-half formalin-fixed, the other frozen in liquid nitrogen for tissue concentration determination. Brain, liver, and skeletal muscle (M. gastrocnemius) were also collected and weighed. Samples from liver and skeletal muscle tissue were frozen for tissue concentration determinations, or fixed in buffered formalin for histopathology investigations.
Histopathology
Kidneys, fixed for $48 h in neutral phosphate-buffered formalin, were embedded in paraffin wax, sectioned and stained with hematoxylin and eosin for histopathologic evaluation.
Electron microscopy
Electron microscopy was performed on selected formalin-fixed kidneys with histopathological findings. Samples were taken from cortex close to the capsule of the kidneys and fixed with 3% glutaraldehyde in 0.1 mol/l cacodylate buffer, pH 7.4, overnight at 4 C and 1% OsO 4 in 0.1 mol/l cacodylate buffer, pH 7.4, for 2 h at 4 C. After post-fixation, the tissues were dehydrated in graded acetone solutions and embedded in Epon. For electron microscopic evaluation, semi-thin sections were prepared from kidney tissue blocks of all animals, stained with toluidine blue and examined with a Zeiss light microscope. Based on these light microscopic investigations, ultra-thin sections from selected tissue blocks were counterstained with uranyl acetate and lead citrate and examined with a FEI Tecnai Spirit (Hillsboro, Oregon) transmission electron microscope.
Immunohistochemistry of a2-microglobulin
Immunohistochemistry was performed using the fully automated instrument Ventana Discovery XT V R (Roche Diagnostics Schweiz AG, Rotkreuz, Switzerland). All chemicals were also provided by Roche Diagnostics. Formalin-fixed paraffin-embedded sections were de-paraffinized and rehydrated under solvent-free conditions (EZprep solution) followed by either antigen retrieval (demasking) performed by heat retrieval cycles in a Tris-EDTA-based buffer (CC1 solution, option standard) or enzymatic digestion (Protease 1 for 16 min). Subsequently slides were blocked using 1Â casein solution in PBS (BioFX laboratories Inc, Owings Mills, Maryland; catalog number PBSC-0100-5x) and endogenous avidin/biotin activity was quenched for 4 min. Primary antibody diluted in antibody diluent was added on slides and incubated at room temperature (a2-microglobulin from R&D Systems, Minneapolis, Minnesota; MAB586, 1/10). A short post-fixation (glutaraldehyde at 0.05%) was done before applying a biotin conjugated secondary antibody diluted at 1/ 500 for 16 min (Jackson Immunoresearch Inc., West Grove, Pennsylvania). Detection was performed with a streptavidinbiotin peroxydase detection system DABMap V R kit (Roche Diagnostics) following the manufacturer recommendations. Slides were counter-stained with hematoxylin and bluing reagent, dehydrated and mounted using Pertex V R (Biosystems Switzerland AG, Nunningen, Switzerland).
RESULTS
Toxicokinetics
The toxicokinetic data demonstrated that all treated animals were systemically exposed to the respective study drug in plasma and in tissues. T max in plasma was observed at 1-h postdose for all study drugs except at 3-h post-dose for telbivudine at 1600 mg/kg (Table 1) . Plasma exposure to study drugs increased approximately proportionally with the dose.
Plasma, kidney, and liver concentrations of the study drugs at necropsy (between 1 and 2 h after last dose) were in a similar range after 3, 10, and/or 28 days of treatment. The kidney and liver to plasma concentration ratios of the test drugs at necropsy were as follows: telbivudine % entecavir < adefovir < tenofovir (Tables 2 and 3 ). The muscle (M. gastrocnemius) levels of the test drugs were similar to kidney and liver concentrations for telbivudine, but slightly to markedly lower for the other study drugs. The muscle concentrations of the study drugs in relation to their plasma levels at necropsy were: tenofovir (300 mg/kg) % adefovir (28 mg/kg) < entecavir (3 mg/kg)% telbivudine (1600 mg/kg) ( Table 4 ).
In-Life Observations
In-life observations revealed clinical signs of toxicity in animals treated with tenofovir at 1000 mg/kg or 600 mg/kg, which indicated a poor general health condition with progressive body weight loss (between À9.0% and À18.2% of initial weight) and led to early sacrifice on Days 6 or 7, respectively. Post-mortem examinations identified lesions in the gastrointestinal tract as cause of moribundity. No similar findings were identified for other compounds. Animals treated with tenofovir at 300 mg/kg and adefovir at 28 mg/kg gained slightly less body weight when compared with controls. No toxicologically relevant effects on body weight were noted for animals treated with telbivudine or entecavir throughout the 28 days of study.
Integrated Assessment of Anatomic Pathology, Molecular Pathology, and Clinical Biochemistry Adefovir Treatment with adefovir resulted in kidney mottling/discoloration and/or enlargement in an individual animal at 11 mg/kg on Day 28, and in 7 out of 8 animals at 28 mg/kg on Day 28. Histopathological correlates of minimal to severe tubular degeneration/regeneration were observed on Day 28 in all animals treated with adefovir at 28 mg/kg, which was characterized by varying degrees of cell flattening, with basophilic cytoplasm, karyomegaly, scattered mitotic figures, and single cell necrosis mainly affecting the proximal tubuli of the upper cortex (Figure 1) . NA, not applicable, no corresponding plasma concentration for these groups; SD, standard deviation; n, number of animals.
In addition, animals treated with adefovir at 11 or 28 mg/kg showed a minimal increase in the incidence of tubular hyaline droplets which were positive to a2-microglobulin by immunohistochemistry, however, there was no clear relationship to the dose and time point (data not shown). More detailed examinations by electron microscopy of the proximal and cortical collecting tubules showed presence of large cytolysosomes filled with mitochondria at different stages of degradation (Figure 2 ). In the urine of animals treated with adefovir at 28 mg/kg on Day 27 (Figure 3) , an increase in creatinine-normalized kidney injury protein markers relative to controls were also observed, with an average increase of 23.5-fold for Kim-1, 6.4-fold for Osteopontin, 5.5-fold for beta-2 microglobulin, 5.4-fold for calbindin and 2.7-fold for neutrophil gelatinase-associated lipocalin (NGAL), together with an average increase in total urinary protein concentration of þ86%. Only one of the treated animals on Day 27 showed an additional marked increase in urinary, creatinine-normalized, Cystatin C (21.8-fold), which was accompanied by increase in urinary clusterin (4.0-fold) and marked glucosuria (3þ based on urine test strip evaluation) in this animal. Slight to moderate increases in urinary, creatininenormalized, calcium (2.5-to 3.8-fold) and phosphorus (30-216%) concentrations were also observed in the animals treated at 28 mg/kg, starting on Day 9. No significant change of GFR, as measured by creatinine or cystatin c clearance rate, were detected in Changes in the proximal tubules were characterized by varying degrees of cell flattening, with basophilic cytoplasm and enlarged nuclei (karyomegaly) (B). Occasional individual necrotic cells, often sloughed in the lumen (arrow), were also seen (B). The interstitium was enriched by a scant inflammatory cell infiltrate (arrow heads).
Bar ¼ 50 lm.
any of the animals treated with adefovir (data not shown). This is in contrast to the measured reduction of GFR detected by MRI in the same animals as described below.
Tenofovir
Treatment groups with tenofovir at 1000 mg/kg or 600 mg/kg were euthanized on Days 6 or 7, respectively, due to progressive body weight and/or clinical signs indicating poor health condition. Post-mortem examinations identified lesions in the gastrointestinal tract (erosions/ulcerations, associated with inflammatory changes) as cause of moribundity. The observed clinical pathology changes (data not shown) were also considered to be associated with the overall poor condition of the animals caused by gastrointestinal lesions, the white arrow points to secondary lysosomes and the black arrow points to basal lamina. In (B), the white arrow points to cytolysosomes containing remnants of mitochondria and the black arrow points to enlarged cytolysosomes/autophagic vacuoles. Top pictures have magnification of 1200Â and the scale bar represents 20 mm, and bottom pictures have magnification of 11 000Â and the scale bar represents 2 mm.
FIG. 3.
Urinary kidney biomarkers from rat treated with adefovir. Treatment-related changes were only observed after treatment with adefovir, and only for the following markers: KIM-1, Osteopontin, Beta-2 microglobulin, Calbindin, and NGAL. Statistical analysis between control and treatment group at the corresponding time point was performed with Dunnett's multiple comparison test, with significance levels of P < .0001, P < .01 and P < .05 represented by 3, 2 and 1 star, respectively.
thereby not enabling a clear interpretation of potential direct renal effects. In animals receiving tenofovir at 300 mg/kg, no histopathological sign of kidney degeneration was detected. However, a distinct increase in tubular hyaline droplets, which was positive to a2-microglobulin by immunohistochemistry was observed after 28 days of treatment (Figure 4) . Moreover, electron microscopy investigations showed increased numbers of secondary lysosomes filled with condensed fibrillar electron-dense material were seen in the proximal convolute tubule epithelial cells (data not shown). Clinical pathology showed increases in urine creatinine-normalized calcium (þ86 to þ120%) and phosphorus (þ51 to 203%) concentrations starting from 9 days at 300 mg/kg. No significant change of GFR, as measured by creatinine or cystatin c clearance rate, were detected in any of the animals treated with tenofovir (data not shown).
Telbivudine
Treatment with telbivudine at 600 or 1600 mg/kg for 28 days did not result in any macroscopic kidney alterations, or any sign of nephrotoxicity as evaluated by histopathology and clinical biochemistry. Minimal time-and dose-dependent increases in the incidence and severity of tubular hyaline droplets were detected, however, without any other correlating histopathological alterations. An increased urine creatinine-normalized calcium concentration (1.8-to 2.8-fold) was noted on Day 2 at 1600 mg/kg, but the significance of this finding remained unclear in the absence of histopathological findings in the kidneys of these animals. No significant change of GFR, as measured by creatinine or cystatin c clearance rate, were detected in any of the animals treated with telbuvidine (data not shown).
Entecavir
Following entecavir treatment at 1 or 3 mg/kg for 28 days, no macroscopic kidney alterations or clinical pathology changes were reported. A minimal increase in the incidence and/or severity of tubular hyaline droplets without a clear relationship to the dose or the duration of the treatment was reported. On Day 3, entecavir at ! 1 mg/kg caused a minimal increase in the severity of tubular basophilia as compared with the controls, however, without corresponding clinical pathology. The finding was not seen at later time points. No significant change of GFR, as measured by creatinine or cystatin c clearance rate, was detected in any of the animals treated with entecavir (data not shown).
Assessment of Kidney Function by Magnetic Resonance Imaging
Following the bolus injection of the contrast agent, MRI monitored the passage of the contrast agent through the renal system in a time-resolved manner, thus yielding a measure for the kidney function. This procedure is based on the fact that Gd-DOTA is predominantly excreted though the kidneys without tubular secretion or reabsorption (Allard et al., 1988; Katzberg et al., 1990; Rohrschneider et al., 2003) ; thus, the main route of its elimination is glomerular filtration. The intravenous injection of Gd-DOTA leads to sequential signal intensity changes, first in the kidney cortex, then in the outer stripe and finally in the inner stripe of the outer medulla ( Figure 5 ). The time-to-peak (TTP) of signal intensity (related to the local Gd-DOTA concentration) in each of the 3 regions reflects the capacity of the kidney to clear the contrast agent, and it has previously been shown that a delayed TTP is consistent with a reduced GFR (Laurent et al., 2002) . Thus, in the present study, TTP in cortex, the outer and the inner stripe of the outer medulla were determined as markers of kidney function.
Evaluation of the renal function by MRI analysis revealed changes primarily on Day 28 in the kidney cortex of animals treated with adefovir at 28 mg/kg (Figure 6 ). No changes were observed in medullary regions at any time point (data not shown). The most prominent alterations included increased (delayed) time-to-peak (TTP) values of the contrast agent in the kidney cortex of animals treated with adefovir at 28 mg/kg for 28 days, which suggest a reduced GFR (Figure 7 ). Small and transient, but significant, increases in the cortical TTP were detected on Day 3 for the high doses of tenofovir (600 mg/kg), entecavir (3 mg/kg) and adefovir (28 mg/kg) in comparison to controls (Figure 7) . However, on Day 10, no significant changes were detected for any of the treatment groups in comparison to the controls (Figure 7) . A slight time-dependent increase in TTP was observed in the vehicle-treated rats (Figure 7 ; TTP day 3: 22.163.9 s (means6SD) vs TTP day 28: 29.061.6 s, P < .001), which might have been due to aging of the animals although other factors cannot be excluded as MRI profiles were recorded on different days (eg, 3-, 10-, or 28-day treatment period). A significant increase in AUC was observed only in the kidney cortex of rats treated with adefovir (28 mg/kg) for 28 days (198.1611.8 mM s in the adefovir group vs 127.1615.4 mM s in controls, means6SD, P < .001).
DISCUSSION
Understanding the safety of various nucleos(t)ides with regard to kidney function is critical, and can be a matter of life and death for patients who may already have renal impairment due to the viral disease itself. While post-marketing surveillance studies and clinical trials have shown that some nucleos(t)ide analogues such as adefovir and tenofovir are associated with cases of nephrotoxicity (Fontana, 2009; Izzedine et al., 2005) , others such as, eg, entecavir have been reported to be safe for the kidney, or even significantly improve the renal filtration rate in patients with compromised kidney function as shown for telbivudine (Chan et al., 2012; Gane et al., 2014; Lee et al., 2015; Li and Zhang, 2015; Liaw et al., 2011a; Qi et al., 2015; Tsai et al., 2014 Tsai et al., , 2015 Yap and Chan, 2015; Zhang et al., 2015) . However, it has also been argued that retrospective analysis of clinical data might have been confounded by the patient's history, life style, and/or other medications. For this reason, the purpose of this exploratory study was to make a comparison of renal safety after repeated administration of adefovir, tenofovir, entecavir, and telbivudine in a nonclinical setting, where the many variables can be better controlled. The study was conducted in Sprague Dawley rats which is a commonly used model for safety investigations of nucles(t)ide analogs that are required by the health authorities. Moreover, nucleos(t)ide analogues have also previously been shown to be converted to their active nucleos(t)ide triphosphate forms in rats (Reddy et al., 2005) .
The results from this comparison study in Sprague Dawley rats showed that repeated treatments with telbivudine at 600 and 1600 mg/kg or entecavir at 1 and 3 mg/kg were not associated with renal toxicity based on functional kidney assessments by MRI, histopathology, and clinical biochemistry data. A small, transient, and statically significant decrease in the GFR was observed for entecavir at 3 mg/kg on Day 3 (Figure 7 ). This was not considered related to the increased tubular basophilia observed at the same time point, as the Gd-DOTA have a predominant renal elimination ($98%) by glomerular filtration without any tubular interference (Grenier et al., 2008) . On Days 10 and 28, there were no significant changes compared with the controls, suggesting a possible adaptive response of the kidney to treatment. No changes in GFRs were observed after treatment with telbivudine to explain the improved renal filtration rate in patients with compromised kidney function as observed in the clinic (Chan et al., 2012; Gane et al., 2014; Lee et al., 2015; Li and Zhang, 2015; Liaw et al., 2011a; Qi et al., 2015; Tsai et al., 2014 Tsai et al., , 2015 Yap and Chan, 2015; Zhang et al., 2015) . However, it should be noted that this study was conducted in healthy rats with GFRs at maximum capacity. In contrast to telbivudine and entecavir that were shown to be safe, both adefovir and   FIG. 4 . Histopathological kidney lesions from rat treated with tenofovir. Panels (A), (C), and (E) represent control, while panels (B), (D) and (F) represent tenofovir-treated rat at 300 mg/kg/day for 28 days. Slight to moderate increase of tubular hyaline droplets appearing in H/E (A and B), which were chromotrope positive at CAB (Chromotrope-Aniline Blue) staining (C and D) and alpha2-microgobluline positive at IHC (E and F) were seen after treatment with tenofovir. Scattered tubular large vacuoles, containing an eosinophilic, homogeneous content inconsistently positive to either CAB and a2-microglobulin were also seen (arrows). Bar ¼ 50 mm.
tenofovir were associated with renal toxicity as discussed next.
The treatment of Sprague Dawley rats with adefovir resulted in nephrotoxicity as manifested by decreased renal function measured by MRI, increased kidney injury markers, and histology findings of the proximal tubule. Importantly, the observed reduction of kidney function was not detected by the gold standard method of GFR measurements (clearance rate of the endogenous marker, creatinine), thereby emphasizing the superiority of MRI in terms of sensitive detection of GFR changes in rats. The adefovir-induced nephrotoxicity in rats recapitulated what has previously been reported for this drug in the clinic (Kahn et al., 1999; Marcellin et al., 2003) , and was obtained after 1 month of daily treatment with adefovir at 28 mg/kg to rats, which corresponded to $22Â of the human equivalent exposure at the recommended therapeutic dose of 10 mg adefovir. In clinical trials, nephrotoxicity was reported after 48 weeks of daily treatment with 30 mg adefovir (Marcellin et al., 2003) , however, several cases of nephrotoxicity have also later been associated with treatments of the recommended dose of 10 mg adefovir (Hartono et al., 2013; Law et al., 2012; Wang et al., 2015) .
Tenofovir at 600 mg/kg or higher was not tolerated due to gastrointestinal toxicity. Consequently it was not possible to evaluate a potential direct effect on kidney in these groups. The lower dose of tenofovir at 300 mg/kg was tolerated, although a slight reduction of body weight gain in this group may also be the consequence of the slight gastrointestinal toxicity in this group. From Day 10 and onward, tenofovir at 300 mg/kg resulted in an increasing incidence of nuclear enlargement in the proximal tubule, and moderate increases in urinary creatininenormalized calcium and phosphorus concentrations which may represent an early step in the manifestation of nephrotoxicity. Treatment with tenofovir at 300 mg/kg was also associated with a stronger accumulation of a2-microglobulin in the proximal tubule as compared with the other study drugs, however, this finding was considered to be specific for male rats and of no toxicological significance for humans (Hildebrand et al., 1997; Swenberg, 1993) . In patients, tenofovir has in a number of studies been reported to cause proximal tubular toxicity with preserved or decreased renal function (Cooper et al., 2010; Hall et al., 2011; Karras et al., 2003; Zaidan et al., 2013) . Other manifestations of proximal tubulopathy in individual patients include decreased bone mass to due phosphate wasting and/or calcitriol deficiency (Fernandez-Fernandez et al., 2011) . Moreover, increased urinary excretion of phosphate without changes in serum phosphate levels, estimated GFR and urine protein excretion in patients (Maggi et al., 2012) is consistent with the results of the current rat study after treatment with tenofovir at 300 mg/kg.
The cause of adefovir-and tenofovir-induced nephrotoxicity in humans has been reported to be associated with FIG. 5 . Functional analysis of the kidney using MRI. A, Difference images with respect to the mean image before Gd-DOTA administration at time point 0, illustrating the renal transit of the contrast material for one rat. Note that the signal increase occurs first in the renal cortex, followed by the outer and the inner medulla. B, Demarcation of the ROIs for analysis of the images, and time profiles of Gd-DOTA concentration ([Gd-DOTA]) in the cortex (red), the outer and inner stripes of the outer medulla (yellow and green, respectively), as well as the blood (blue), derived for the corresponding areas in a sequence of dynamic images. Abbreviations: TTP, time-topeak. mitochondrial toxicity. This has been documented by case studies of renal biopsies showing abnormal/depleted mitochondria, increase in urinary cytochrome C as well as wasting of calcitriol which is synthesized by the mitochondria of the proximal tubule (Cote et al., 2006; Herlitz et al., 2010; Kohler et al., 2009; Maggi et al., 2012; Tanji et al., 2001) . Of note, the Fanconi syndrome which has been associated with both, adefovir and tenofovir treatments (Karras et al., 2003; Wang et al., 2015) , is also a typical renal presentation of patients who have pathogenic mutations in mitochondrial DNA (mtDNA) (Martin-Hernandez et al., 2005; Niaudet and Rotig, 1997; Wang et al., 2015) , as well as in patients exposed to other therapies with potential mitochondrial toxicity (Hall and Unwin, 2007; Izzedine et al., 2003) . In our study, tenofovir did, however, not show signs of mitochondrial toxicity, although this might have been due to the too low dose applied owing to the dose limiting gastrointestinal toxicity. On the other hand, adefovir-treatment resulted in mitochondrial degeneration/depletion, as observed by electron microscopy, which may indicate mitochondrial toxicity.
The mechanism of adefovir-and tenofovir-induced mitochondrial toxicity in humans is thought to be related to inhibition of mitochondrial DNA polymerase. In fact, all nucleos(t)ide analogs have a 'black box' warning because of their structural resemblance to endogenous nucleos(t)ides which can potentially be miss-incorporated by the DNA polymerase c, leading to termination of mitochondrial DNA replication and consequently depletion of mitochondrial DNA. While such a mechanism seems theoretically plausible, and has indeed been proven for some nucleos(t)ide analogues in vitro (Hoschele, 2006) , it is not clear to what extent such a mechanism plays a role in vivo. There is 1 case report from a single patient on adefovir-treatment in which histochemical stains of renal biopsies showed deficiency of enzymes partially encoded by mitochondrial DNA while stains for mitochondrial enzymes encoded by nuclear DNA was preserved, thereby indicating defects of mitochondrial DNA replication (Tanji et al., 2001) . However, this patient had received multiple treatments, including another nucleoside analog, stavudine, which may have impacted the results (Bendele and Richardson, 2002; Menezes et al., 2013) . Likewise, it has also been disputed that the observation of mitochondrial DNA depletion in patients treated with tenofovir may also have been confounded by treatments with other nucles(t)ide analogues, such as, eg, didanosine (Cote et al., 2006) . In order to obtain a more comprehensive insight into the mitochondrial toxic mechanism of nucleos(t)ide analogues, in vitro and animal experiments have been conducted. However, while in vitro studies with isolated human mitochondrial DNA polymerase b and c has clearly demonstrated inhibition by some nucles(t)ide analogues (Hoschele, 2006) , only modest inhibition have been obtained by adefovir and tenofovir (Brinkman et al., 1998; Lee et al., 2003) . Moreover, no depletion of mitochondrial DNA have been observed after long-term treatment of various primary or immortalized human cell cultures with adefovir and tenofovir, as in contrast to other nucles(t)ides (Birkus et al., 2002 (Birkus et al., , 2003 Hoschele, 2006; Venhoff et al., 2007) . Conversely, animal FIG. 7 . Average time to peak (TTP) determined from the Gd-DOTA concentration time profiles in the kidney cortex on Days 3, 10, and 28 for the different treatment groups. Error bars represent SD, and the levels of significance correspond to comparisons between control and treated rats, using ANOVA with random effects comparisons (Bonferroni correction). Contrast agent was injected as bolus at time point 0.
studies have been more informative, but only for some nucles(-t)ides, such as, eg, tenofovir. For instance, treatment of Sprague Dawley rats with tenofovir at 100 mg/kg for 8 weeks has demonstrated reduction of mtDNA copy numbers and impaired expression of mtDNA-encoded cytochrome c oxidase (COX) I but not nucleus-encoded COX IV subunits, thereby demonstrating impairment of mitochondrial DNA polymerase (Lebrecht et al., 2009) . Another study has shown impaired mitochondrial respiratory function after administration of tenofovir (600 mg/kg) administered to male Wistar rats for 5 weeks (Ramamoorthy et al., 2014) . Of note, no gastrointestinal toxicity was reported in these studies, as in contrast to our study which thus limited our analysis of direct effects on the kidney of animals in the tenofovir group. In contrast to tenofovir, a previously reported study in Sprague Dawley rats treated with adefovir at 40 mg/kg for 28 days has not shown obvious effects on mitochondrial DNA replication (Zhu et al., 2012) .
With the lack of data providing a mechanistic explanation for the observed degraded/depleted mitochondria in the adefovir group of our study, it remains difficult to discriminate between the cause and effect-relationship. In other words, it cannot be ruled out whether the degraded/depleted mitochondria observed by electron microscopy in the adefovir group of our study was due to direct mitochondrial toxicity, or whether there were multifactorial toxicities consequently leading to mitochondrial degradation. Moreover, it is also possible that there may not be a universal toxic mechanism of all nucleos(t)ide analogues, and that their toxicity may not necessarily involve inhibition of mitochondrial polymerase c (Lund et al., 2007) . To this end, it has also been speculated that the pro-drug moiety of adefovir, dipivoxil ester, or the fumarate salt of tenofovir may also play a role in nephrotoxicity (Hohenegger et al., 1989; Kakuda, 2000) .
Irrespective of the mechanisms behind, the goal of this study was to compare the renal safety of adefovir, tenofovir, telbivudine, and entecavir. While adefovir was clearly shown to be nephrotoxic and tenofovir was shown to have some effects on the kidney, both telbivudine and entecavir were demonstrated to be safe. Accordingly, the relative safety with regard to kidney function and morphology in rats can be ranked as follows: telbivudine ¼ entecavir > tenofovir ) adefovir, at similar multiples of human dose. To this end it is important to note that adefovir and tenofovir were shown to have a higher kidney/plasma concentration ratio compared telbivudine and entecavir at HED in this study. It is therefore possible that the effect of adefovir and tenofovir on the kidney may be a direct consequence of higher transporter uptake of these compounds into the proximal tubule cells, as compared with the other study drugs.
In conclusion, the study results reported here are in accordance with the experience based on the use of adefovir, tenofovir, entecavir, and telbivudine in clinical practice (Fung et al., 2014; Koklu et al., 2015; Lee et al., 2015; Li and Zhang, 2015; Pipili et al., 2014; Tsai et al., 2015; Zhang et al., 2015) . These previously reported clinical studies also showed superiority of telbivudine and entecavir in terms of renal safety, however, it should be mentioned that a direct head to head comparison of adefovir, tenofovir, entecavir, and telbivudine in treatment naive patients with normal kidney function has not been conducted yet, thereby emphasizing the value of this nonclinical comparison study.
